Daniel Menzies, MBChB, Arun Nair, MBBS, Karen T

Slides:

Advertisements

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Advertisements

Nasal filters for the treatment of allergic rhinitis: A randomized, double-blind, placebo- controlled crossover clinical trial Peter Kenney, BA, BSc,

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Alveolar nitric oxide and asthma control in mild untreated asthma

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity Andrei Malinovschi,

Reduced exhaled nitric oxide values in children with asthma after inpatient rehabilitation at high altitude Johannes Huss-Marp, MD, Ursula Krämer, PhD,

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Fatty acids, inflammation, and asthma

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma Virginia Norris, MRCP, Lee Choong, BSc, Duyen Tran,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Effect of montelukast for treatment of asthma in cigarette smokers

Current application of exhaled nitric oxide in clinical practice

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Fatty acids, inflammation, and asthma

Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: A random-sample population study Asger Sverrild, MD, Celeste Porsbjerg,

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol Ian D. Pavord, DM, FRCP, Peter K. Jeffery,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Nasal filters for the treatment of allergic rhinitis: A randomized, double-blind, placebo- controlled crossover clinical trial Peter Kenney, BA, BSc,

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Asthma treatment and asthma prevention: A tale of 2 parallel pathways

Masqueraders of exercise-induced vocal cord dysfunction

Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma Arvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff,

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12- month follow-up analysis Pranabashis Haldar, MD, Christopher E. Brightling,

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Early decreases in blood eosinophil levels with reslizumab

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Kaiser Lim, MD, James T. Li, MD, PhD

Lisa G. Wood, PhD, Manohar L. Garg, PhD, Peter G. Gibson, MBBS

Effect of ingested H1 antihistamines on methacholine challenge

Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: A random-sample population study Asger Sverrild, MD, Celeste Porsbjerg,

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

What is an “eosinophilic phenotype” of asthma?

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis Sriram Vaidyanathan, MBBS, Peter Williamson,

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Levels of nitric oxide oxidation products are increased in the epithelial lining fluid of children with persistent asthma Anne M. Fitzpatrick, PhD, Lou.

Risk of oral food challenges

Nitric oxide as a clinical guide for asthma management

Treatment of airway inflammation improves exercise pulmonary gas exchange and performance in asthmatic subjects Hans C. Haverkamp, PhD, Jerome A. Dempsey,

Eckard Hamelmann, MD, Eric D

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Nasal challenge with allergen leads to maxillary sinus inflammation

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Perception of risk associated with asthma research procedures among adolescents, parents, and pediatricians Robert D. Annett, PhD, Janet L. Brody, PhD,

Eight-year outcomes of the Childhood Asthma Prevention Study

Valérie Bougault, PhD, Julie Turmel, MSc, Louis-Philippe Boulet, MD

Systemic responses after bronchial aspirin challenge in sensitive patients with asthma Joanna S. Makowska, MD, PhD, Janina Grzegorczyk, PhD, Barbara Bienkiewicz,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Differences in airway remodeling between subjects with severe and moderate asthma Carmela Pepe, MD, Susan Foley, MD, Joanne Shannon, MD, Catherine Lemiere,

Primary prevention of asthma and allergy

Mast cell–associated alveolar inflammation in patients with atopic uncontrolled asthma Cecilia K. Andersson, PhD, Anders Bergqvist, MSc, Michiko Mori,

Presentation transcript:

Effect of aspirin on airway inflammation and pulmonary function in patients with persistent asthma Daniel Menzies, MBChB, Arun Nair, MBBS, Karen T. Meldrum, BSc, Pippa Hopkinson, Brian J. Lipworth, MD Journal of Allergy and Clinical Immunology Volume 121, Issue 5, Pages 1184-1189.e4 (May 2008) DOI: 10.1016/j.jaci.2008.01.009 Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Study diagram. AS, Aspirin; PL, placebo to aspirin. Journal of Allergy and Clinical Immunology 2008 121, 1184-1189.e4DOI: (10.1016/j.jaci.2008.01.009) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Effect of treatment with aspirin and placebo on histamine challenge. Doubling-dilution shift from baseline for individual patients and mean difference with 95% CI after treatment with aspirin and placebo are shown. There was no significant difference (P = 1) for aspirin compared with placebo. Journal of Allergy and Clinical Immunology 2008 121, 1184-1189.e4DOI: (10.1016/j.jaci.2008.01.009) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Effect of treatment with aspirin and placebo on tidal nitric oxide. Mean and SEM (error bars) exhaled nitric oxide levels at baseline and after treatment with aspirin and placebo on a log10 scale are shown. There was no significant difference (P = 1) for aspirin compared with placebo. Journal of Allergy and Clinical Immunology 2008 121, 1184-1189.e4DOI: (10.1016/j.jaci.2008.01.009) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Effect of treatment with aspirin and placebo on alveolar nitric oxide and bronchial flux. Mean and SEM (error bars) alveolar nitric oxide (distal airway inflammation) and bronchial flux (proximal airway inflammation) at baseline and after treatment with aspirin and placebo on a log10 scale are shown. There was no significant difference (P = 1) for aspirin compared with placebo. Journal of Allergy and Clinical Immunology 2008 121, 1184-1189.e4DOI: (10.1016/j.jaci.2008.01.009) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Effect of treatment with aspirin and placebo on spirometry and peak flow variability. Mean and SEM (error bars) FEV1, forced expiratory flow between 25% and 75% (FEF 25-75) of exhalation (both percent predicted), and peak expiratory flow (PEF) variability (absolute percentage) at baseline and after treatment with aspirin and placebo are shown. There was no significant difference (P = 1) for aspirin compared with placebo. Journal of Allergy and Clinical Immunology 2008 121, 1184-1189.e4DOI: (10.1016/j.jaci.2008.01.009) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 6 Effect of treatment with aspirin and placebo on thromboxane B2 and 15-epilipoxin A4. Mean and SEM (error bars) thromboxane B2 and 15-epilipoxin A4 levels at baseline and after treatment with aspirin and placebo on a log10 scale are shown. Significant difference from both baseline and placebo: P < .001. Journal of Allergy and Clinical Immunology 2008 121, 1184-1189.e4DOI: (10.1016/j.jaci.2008.01.009) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Individual change in exhaled nitric oxide levels. Journal of Allergy and Clinical Immunology 2008 121, 1184-1189.e4DOI: (10.1016/j.jaci.2008.01.009) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Individual change in thromboxane levels. Journal of Allergy and Clinical Immunology 2008 121, 1184-1189.e4DOI: (10.1016/j.jaci.2008.01.009) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Individual change in lipoxin levels. Journal of Allergy and Clinical Immunology 2008 121, 1184-1189.e4DOI: (10.1016/j.jaci.2008.01.009) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions